Amesika N. Nyaku
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amesika N. Nyaku has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Babafemi O. Taiwo
Division of Infectious Diseases, Northwestern University Feinberg School of Medicine Chicago, IL 60611, USA
5 shared publications Paul E Sax
Division of Infectious Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachussetts
4 shared publicationsBaiba Berzins
Division of Infectious Diseases, Northwestern University, Chicago, Illinois
3 shared publicationsCatherine Godfrey
Division of AIDS, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland
3 shared publicationsLu Zheng
Harvard T.H. Chan School of Public Health, Boston, Massachusetts
3 shared publicationsBabafemi O Taiwo
Division of Infectious Diseases, Northwestern University, Chicago, Illinois
2 shared publications
Latest Publications
- Open Access
- 28 February 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (3) , ofaf120
Perceptions of People Who Inject Drugs About Long-acting Medications for Opioid Use Disorder, Preexposure Prophylaxis, and Antiretroviral Therapy
Background: Long-acting injectable (LAI) forms of preexposure prophylaxis and antiretroviral therapy and extended-release medications for opioid use disorder (OUD) may reduce HIV and OUD treatment attrition, but community interest among people who inject drugs remains underexplored. Methods: From September to December 2023, we conducted a cross-sectional survey of adults with OUD and a history of injection drug use who were attending a New Jersey syringe exchange program to assess their experiences with HIV and OUD care and their knowledge, attitudes, and preferences about LAI. Results: Of 193 participants, 15 were persons with HIV (PWH), 72 were high risk for HIV (HRH), and 91 were low risk for HIV (LRH). Many participants had previously taken medications for OUD (60%), but knowledge of extended-release medications for OUD was low (40% PWH, 45.8% HRH, 41.6% LRH, P = .85). Participant interest in extended-release naltrexone (33.3% PWH, 27.8% HRH, 26.7% LRH, P = .91) and extended-release buprenorphine (33.3% PWH, 18.3% HRH, 20.9% LRH, P = .45) was also low. Preexposure prophylaxis knowledge was high (59.1% HRH, 63.9% LRH, P = .54), but prior usage (11.1% HRH, 6.7% LRH, P = .32) and interest (18.1% HRH, 21.1% LRH P = .63) in LAI preexposure prophylaxis were low. PWH had high awareness (66.7%) and interest (66.7%) in receiving LAI antiretroviral therapy. Interest in integrated care was greater for PWH (69.2%) than for those at HRH (29.8%) or LRH (33.9%; P = .03), and preferred treatment locations varied among the groups. Conclusions: Targeted education and outreach are particularly needed for extended-release medications for OUD and LAI preexposure prophylaxis. A differentiated care model may better address the needs of people who inject drugs with OUD, whether at risk for or with HIV. Addressing barriers to LAI treatment remains essential.
- 28 February 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (3) , ofaf120
Open AccessPerceptions of People Who Inject Drugs About Long-acting Medications for Opioid Use Disorder, Preexposure Prophylaxis, and Antiretroviral Therapy
Background: Long-acting injectable (LAI) forms of preexposure prophylaxis and antiretroviral therapy and extended-release medications for opioid use disorder (OUD) may reduce HIV and OUD treatment attrition, but community interest among people who inject drugs remains underexplored. Methods: From September to December 2023, we conducted a cross-sectional survey of adults with OUD and a history of injection drug use who were attending a New Jersey syringe exchange program to assess their experiences with HIV and OUD care and their knowledge, attitudes, and preferences about LAI. Results: Of 193 participants, 15 were persons with HIV (PWH), 72 were high risk for HIV (HRH), and 91 were low risk for HIV (LRH). Many participants had previously taken medications for OUD (60%), but knowledge of extended-release medications for OUD was low (40% PWH, 45.8% HRH, 41.6% LRH, P = .85). Participant interest in extended-release naltrexone (33.3% PWH, 27.8% HRH, 26.7% LRH, P = .91) and extended-release buprenorphine (33.3% PWH, 18.3% HRH, 20.9% LRH, P = .45) was also low. Preexposure prophylaxis knowledge was high (59.1% HRH, 63.9% LRH, P = .54), but prior usage (11.1% HRH, 6.7% LRH, P = .32) and interest (18.1% HRH, 21.1% LRH P = .63) in LAI preexposure prophylaxis were low. PWH had high awareness (66.7%) and interest (66.7%) in receiving LAI antiretroviral therapy. Interest in integrated care was greater for PWH (69.2%) than for those at HRH (29.8%) or LRH (33.9%; P = .03), and preferred treatment locations varied among the groups. Conclusions: Targeted education and outreach are particularly needed for extended-release medications for OUD and LAI preexposure prophylaxis. A differentiated care model may better address the needs of people who inject drugs with OUD, whether at risk for or with HIV. Addressing barriers to LAI treatment remains essential.
- Open Access
- 1 January 2025
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Infectious Diseases
- Vol. 4 (1)
Disruptions to the United States’ Research Portfolio in 2025 and Potential Global Consequences
At the start of 2025, the world was healthier and safer because of the USA’s longstanding commitment to biomedical research.1–3 Further progress was on the
- 1 January 2025
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Infectious Diseases
- Vol. 4 (1)
Open AccessDisruptions to the United States’ Research Portfolio in 2025 and Potential Global Consequences
At the start of 2025, the world was healthier and safer because of the USA’s longstanding commitment to biomedical research.1–3 Further progress was on the
- Open Access
- 1 June 2024
- Published by Taylor & Francis in Annals of Medicine
- Vol. 56 (1) , 2355566
The role of recovery peer navigators in retention in outpatient buprenorphine treatment: a retrospective cohort study
Racial and ethnic disparities are evident in the accessibility of treatment for opioid use disorder (OUD). Even when medications for OUD (MOUD) are accessible, racially and ethnically minoritized groups have higher attrition rates from treatment. Existing literature has primarily identified the specific racial and ethnic groups affected by these disparities, but has not thoroughly examined interventions to address this gap. Recovery peer navigators (RPNs) have been shown to improve access and overall retention on MOUD. In this retrospective cohort study, we evaluate the role of RPNs on patient retention in clinical care at an outpatient program in a racially and ethnically diverse urban community. Charts were reviewed of new patients seen from January 1, 2019 through December 31, 2019. Sociodemographic and clinical visit data, including which providers and services were utilized, were collected, and the primary outcome of interest was continuous retention in care. Bivariate analysis was done to test for statistically significant associations between variables by racial/ethnic group and continuous retention in care using Student's t-test or Pearson's chi-square test. Variables with p value ≤0.10 were included in a multivariable regression model. A total of 131 new patients were included in the study. RPNs improved continuous retention in all-group analysis (27.6% pre-RPN compared to 80.2% post-RPN). Improvements in continuous retention were observed in all racial/ethnic subgroups but were statistically significant in the non-Hispanic Black (NHB) group (p < 0.001). Among NHB, increases in continuous retention were observed post-RPN in patients with male sex (p < 0.001), public health insurance (p < 0.001), additional substance use (p < 0.001), medical comorbidities (p < 0.001), psychiatric comorbidities (p = 0.001), and unstable housing (p = 0.005). Multivariate logistic regression demonstrated that patients who lacked insurance had lower odds of continuous retention compared to patients with public insurance (aOR = 0.17, 95% CI 0.039-0.70, p = 0.015). RPNs can improve clinical retention for patients with OUD, particularly for individuals experiencing several sociodemographic and clinical factors that are typically correlated with discontinuation of care.
- 1 June 2024
- Published by Taylor & Francis in Annals of Medicine
- Vol. 56 (1) , 2355566
Open AccessThe role of recovery peer navigators in retention in outpatient buprenorphine treatment: a retrospective cohort study
Racial and ethnic disparities are evident in the accessibility of treatment for opioid use disorder (OUD). Even when medications for OUD (MOUD) are accessible, racially and ethnically minoritized groups have higher attrition rates from treatment. Existing literature has primarily identified the specific racial and ethnic groups affected by these disparities, but has not thoroughly examined interventions to address this gap. Recovery peer navigators (RPNs) have been shown to improve access and overall retention on MOUD. In this retrospective cohort study, we evaluate the role of RPNs on patient retention in clinical care at an outpatient program in a racially and ethnically diverse urban community. Charts were reviewed of new patients seen from January 1, 2019 through December 31, 2019. Sociodemographic and clinical visit data, including which providers and services were utilized, were collected, and the primary outcome of interest was continuous retention in care. Bivariate analysis was done to test for statistically significant associations between variables by racial/ethnic group and continuous retention in care using Student's t-test or Pearson's chi-square test. Variables with p value ≤0.10 were included in a multivariable regression model. A total of 131 new patients were included in the study. RPNs improved continuous retention in all-group analysis (27.6% pre-RPN compared to 80.2% post-RPN). Improvements in continuous retention were observed in all racial/ethnic subgroups but were statistically significant in the non-Hispanic Black (NHB) group (p < 0.001). Among NHB, increases in continuous retention were observed post-RPN in patients with male sex (p < 0.001), public health insurance (p < 0.001), additional substance use (p < 0.001), medical comorbidities (p < 0.001), psychiatric comorbidities (p = 0.001), and unstable housing (p = 0.005). Multivariate logistic regression demonstrated that patients who lacked insurance had lower odds of continuous retention compared to patients with public insurance (aOR = 0.17, 95% CI 0.039-0.70, p = 0.015). RPNs can improve clinical retention for patients with OUD, particularly for individuals experiencing several sociodemographic and clinical factors that are typically correlated with discontinuation of care.
- Open Access
- 8 February 2024
- Published by Springer Nature in BMC Health Services Research
- Vol. 24 (1) , 1-10
A survey of barriers and facilitators to the adoption of buprenorphine prescribing after implementation of a New Jersey-wide incentivized DATA-2000 waiver training program
Background: Opioid-involved overdose deaths continue to rise in the US, despite availability of highly effective treatments for opioid use disorder (OUD), in part due to the insufficient number of treatment providers. Barriers include the need for providers to gain expertise and confidence in providing MOUD to their patients who need these treatments. To mitigate this barrier, New Jersey sponsored a buprenorphine training program with financial incentives for participation, which met the then existing requirement for the DATA-2000 waiver. In a 2019 follow-up survey, participants reported on barriers and facilitators to subsequent buprenorphine prescribing. Methods: Participants in the training program completed a 10-min electronic survey distributed via email. The survey addressed demographics, practice characteristics, current buprenorphine prescribing, and barriers and facilitators to adoption and/or scale up of buprenorphine prescribing. Results: Of the 440 attendees with a valid email address, 91 individuals completed the survey for a response rate of 20.6%. Of the 91 respondents, 89 were eligible prescribers and included in the final analysis. Respondents were predominantly female (n = 55, 59.6%) and physicians (n = 55, 61.8%); representing a broad range of specialties and practice sites. 65 (73%) of respondents completed the training and DEA-registration, but only 31 (34.8%) were actively prescribing buprenorphine. The most frequently cited barriers to buprenorphine prescribing were lack of access to support services such as specialists in addiction, behavioral health services, and psychiatry. The most frequently reported potential facilitators were integrated systems with direct access to addiction specialists and psychosocial services, easier referral to behavioral health services, more institutional support, and improved guidance on clinical practice standards for OUD treatment. Conclusion: More than half (52.3%) of those who completed incentivized training and DEA registration failed to actively prescribe buprenorphine. Results highlight provider perceptions of inadequate availability of support for the complex needs of patients with OUD and suggest that broader adoption of buprenorphine prescribing will require scaling up support to clinicians, including increased availability of specialized addiction and mental health services.
- 8 February 2024
- Published by Springer Nature in BMC Health Services Research
- Vol. 24 (1) , 1-10
Open AccessA survey of barriers and facilitators to the adoption of buprenorphine prescribing after implementation of a New Jersey-wide incentivized DATA-2000 waiver training program
Background: Opioid-involved overdose deaths continue to rise in the US, despite availability of highly effective treatments for opioid use disorder (OUD), in part due to the insufficient number of treatment providers. Barriers include the need for providers to gain expertise and confidence in providing MOUD to their patients who need these treatments. To mitigate this barrier, New Jersey sponsored a buprenorphine training program with financial incentives for participation, which met the then existing requirement for the DATA-2000 waiver. In a 2019 follow-up survey, participants reported on barriers and facilitators to subsequent buprenorphine prescribing. Methods: Participants in the training program completed a 10-min electronic survey distributed via email. The survey addressed demographics, practice characteristics, current buprenorphine prescribing, and barriers and facilitators to adoption and/or scale up of buprenorphine prescribing. Results: Of the 440 attendees with a valid email address, 91 individuals completed the survey for a response rate of 20.6%. Of the 91 respondents, 89 were eligible prescribers and included in the final analysis. Respondents were predominantly female (n = 55, 59.6%) and physicians (n = 55, 61.8%); representing a broad range of specialties and practice sites. 65 (73%) of respondents completed the training and DEA-registration, but only 31 (34.8%) were actively prescribing buprenorphine. The most frequently cited barriers to buprenorphine prescribing were lack of access to support services such as specialists in addiction, behavioral health services, and psychiatry. The most frequently reported potential facilitators were integrated systems with direct access to addiction specialists and psychosocial services, easier referral to behavioral health services, more institutional support, and improved guidance on clinical practice standards for OUD treatment. Conclusion: More than half (52.3%) of those who completed incentivized training and DEA registration failed to actively prescribe buprenorphine. Results highlight provider perceptions of inadequate availability of support for the complex needs of patients with OUD and suggest that broader adoption of buprenorphine prescribing will require scaling up support to clinicians, including increased availability of specialized addiction and mental health services.
- Open Access
- 19 August 2023
- Published by Elsevier in Preventive Medicine Reports
- Vol. 35, 102374
Overdose education and naloxone distribution program design informed by people who use drugs and naloxone distributors
- 19 August 2023
- Published by Elsevier in Preventive Medicine Reports
- Vol. 35, 102374
Open AccessOverdose education and naloxone distribution program design informed by people who use drugs and naloxone distributors
- Open Access
- 9 June 2022
- Published by Springer Nature in Journal of Racial and Ethnic Health Disparities
- Vol. 10 (4) , 1542-1548
HIV Prevention Research Experiences Among Men Who Have Sex With Men and Transgender Persons of Color
Purpose: Black and Latinx MSM and transgender POC disproportionately experience new HIV diagnoses. Determining effective HIV prevention methods requires the inclusion of these communities in research and thorough post-trial experience evaluations. This study sought to evaluate the experiences of Black and Latinx MSM and transgender POC in HIV prevention research and identify facilitators and barriers to continued trials participation. Methods: A survey was developed in partnership with the community engagement team based on emerging themes during research participant check-ins with the team. The survey was built in REDCap and distributed to participants via text message. The survey assessed experiences with the research process time commitments, study responsibilities, compensation, experiences with Truvada®, characteristics of the research study team and site, barriers to continued study participation, willingness to participate in future studies, and overall satisfaction. All statistical analysis was completed in Stata. Results: Forty-four participants were enrolled in the study. Most participants (98%) were satisfied with their experiences in HIV prevention research. Job or school schedules were the most frequently cited barrier to study participation while Truvada® provision and adequate study visit compensation, length, number, and frequency were facilitators. Participants reported that research staff made them feel comfortable when talking about sexual behaviors, alcohol use, mental health, drug use, housing problems, violence in relationships, and legal problems. Conclusions: Evaluating the experiences of key communities in HIV prevention research can help identify barriers and facilitators to clinical trials engagement and improve the design of future trials.
- 9 June 2022
- Published by Springer Nature in Journal of Racial and Ethnic Health Disparities
- Vol. 10 (4) , 1542-1548
Open AccessHIV Prevention Research Experiences Among Men Who Have Sex With Men and Transgender Persons of Color
Purpose: Black and Latinx MSM and transgender POC disproportionately experience new HIV diagnoses. Determining effective HIV prevention methods requires the inclusion of these communities in research and thorough post-trial experience evaluations. This study sought to evaluate the experiences of Black and Latinx MSM and transgender POC in HIV prevention research and identify facilitators and barriers to continued trials participation. Methods: A survey was developed in partnership with the community engagement team based on emerging themes during research participant check-ins with the team. The survey was built in REDCap and distributed to participants via text message. The survey assessed experiences with the research process time commitments, study responsibilities, compensation, experiences with Truvada®, characteristics of the research study team and site, barriers to continued study participation, willingness to participate in future studies, and overall satisfaction. All statistical analysis was completed in Stata. Results: Forty-four participants were enrolled in the study. Most participants (98%) were satisfied with their experiences in HIV prevention research. Job or school schedules were the most frequently cited barrier to study participation while Truvada® provision and adequate study visit compensation, length, number, and frequency were facilitators. Participants reported that research staff made them feel comfortable when talking about sexual behaviors, alcohol use, mental health, drug use, housing problems, violence in relationships, and legal problems. Conclusions: Evaluating the experiences of key communities in HIV prevention research can help identify barriers and facilitators to clinical trials engagement and improve the design of future trials.
- 1 March 2022
- Published by Elsevier in Addictive Behaviors
- Vol. 126, 107182
Comparisons of injection and non-injection opioid use among Black people in methadone treatment: A pilot in Detroit
- 1 March 2022
- Published by Elsevier in Addictive Behaviors
- Vol. 126, 107182
Comparisons of injection and non-injection opioid use among Black people in methadone treatment: A pilot in Detroit
- 1 January 2022
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 132, 108514
Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms
- 1 January 2022
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 132, 108514
Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms
- 1 September 2021
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 128, 108389
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)
- 1 September 2021
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 128, 108389
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)